<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1455">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05142215</url>
  </required_header>
  <id_info>
    <org_study_id>299940</org_study_id>
    <nct_id>NCT05142215</nct_id>
  </id_info>
  <brief_title>A Placebo-controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention for the Relief of Stable Angina</brief_title>
  <acronym>ORBITA-CTO</acronym>
  <official_title>ORBITA-CTO Pilot: A Comparison of the Impact of CTO PCI Versus Placebo on Angina in Patients With Background Optimal Medical Therapy - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mid and South Essex NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mid and South Essex NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      ORBITA-CTO Pilot is a double blinded randomised placebo-controlled trial comparing the&#xD;
      effects of chronic total occlusion percutaneous coronary intervention versus placebo on&#xD;
      symptoms of angina in patients with background optimal medical therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in angina symptom ordinal scale score between groups</measure>
    <time_frame>24 &amp; 26 weeks</time_frame>
    <description>Change in angina symptom ordinal scale score between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical limitation, angina frequency, angina stability, treatment satisfaction and quality of life scores as measured by the Seattle Angina Questionnaire (SAQ)</measure>
    <time_frame>24 &amp; 26 weeks</time_frame>
    <description>Physical limitation, angina frequency, angina stability, treatment satisfaction and quality of life scores as measured by the Seattle Angina Questionnaire (SAQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAQ summary score</measure>
    <time_frame>24 &amp; 26 weeks</time_frame>
    <description>SAQ summary score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by EQ-5D-5L</measure>
    <time_frame>24 &amp; 26 weeks</time_frame>
    <description>Quality of life as measured by EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rose dyspnea scale</measure>
    <time_frame>24 &amp; 26 weeks</time_frame>
    <description>Change in Rose dyspnea scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peak VO2 and VO2 at AT</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in peak VO2 and VO2 at AT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fidelity of blinding using Bang's blinding index (BI)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Fidelity of blinding using Bang's blinding index (BI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol adherence</measure>
    <time_frame>26 weeks</time_frame>
    <description>Proportion of participants adherent to allocated randomised treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Stable Angina</condition>
  <condition>Chronic Total Occlusion of Coronary Artery</condition>
  <arm_group>
    <arm_group_label>Percutaneous coronary intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous coronary intervention (PCI) for chronic total occlusion (CTO).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo percutaneous coronary intervention</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo procedure for chronic total occlusion (CTO).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>Percutaneous coronary intervention using drug eluting stents and contemporary CTO PCI techniques on background of optimal medical therapy.</description>
    <arm_group_label>Percutaneous coronary intervention</arm_group_label>
    <other_name>Coronary angioplasty</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placebo percutaneous coronary intervention</intervention_name>
    <description>Placebo percutaneous coronary intervention procedure on background of optimal medical therapy.</description>
    <arm_group_label>Placebo percutaneous coronary intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ORBITA CTO will enrol patients who meet all 5 of the following criteria:&#xD;
&#xD;
          1. Accepted for CTO PCI procedure by a specialist CTO operator.&#xD;
&#xD;
          2. Patients with symptoms related to a single vessel CTO (≥3 months duration, or probable&#xD;
             CTO where duration is unknown) in a vessel of at least 2.5mm diameter without&#xD;
             angiographically significant (LMS ≥50%, LAD/Cx/RCA/Graft ≥70%, ≥2mm diameter) coronary&#xD;
             artery stenosis in remaining non-CTO vessels.&#xD;
&#xD;
             Symptoms are:&#xD;
&#xD;
             a) Typical exertional angina defined as: i) constricting discomfort in the front of&#xD;
             the chest or in the neck, jaw, shoulder or arm ii) precipitated by physical exertion&#xD;
             iii) relieved by rest or nitrates within 5 minutes b) Angina symptoms at rest&#xD;
             (including decubitus angina and post-prandial angina).&#xD;
&#xD;
             c) Shortness of breath on exertion considered to be angina equivalent.&#xD;
&#xD;
          3. Clinical evidence of ischaemia in CTO territory on dobutamine stress echocardiography,&#xD;
             nuclear myocardial perfusion scan, stress perfusion CMR or PET).&#xD;
&#xD;
          4. Evidence of viability: If left ventricular angiogram or echocardiogram demonstrates LV&#xD;
             impairment or RWMA then viability must be demonstrated.&#xD;
&#xD;
          5. J-CTO score ≤ 3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute coronary syndrome within 4 weeks.&#xD;
&#xD;
          2. PCI to non-CTO lesion in prior 4 weeks as part of ACS or elective PCI.&#xD;
&#xD;
          3. Non-revascularised clinically important non-CTO vessel.&#xD;
&#xD;
          4. Proven ischaemia (invasive or non-invasive) in non-culprit territory.&#xD;
&#xD;
          5. Contraindications to PCI or drug-eluting stent (DES) implantation.&#xD;
&#xD;
          6. Inability to tolerate or contraindication to DAPT.&#xD;
&#xD;
          7. Severe valvular heart disease.&#xD;
&#xD;
          8. Severe chronic pulmonary disease (FEV1 &lt;30% of predicted value).&#xD;
&#xD;
          9. Severe musculoskeletal disease resulting in immobility.&#xD;
&#xD;
         10. Life expectancy &lt;2years.&#xD;
&#xD;
         11. Pregnancy.&#xD;
&#xD;
         12. Age &lt;18years.&#xD;
&#xD;
         13. Inability to consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Davies, MRCP PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Essex Cardiothoracic Centre, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarosh Khan, MRCP</last_name>
    <role>Study Director</role>
    <affiliation>Essex Cardiothoracic Centre, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Davies, MRCP PhD</last_name>
    <phone>01268 524900</phone>
    <email>john.davies32@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarosh Khan, MRCP</last_name>
    <phone>01268 524900</phone>
    <phone_ext>4211</phone_ext>
    <email>sarosh.khan2@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Essex Cardiothoracic Centre</name>
      <address>
        <city>Basildon</city>
        <state>Essex</state>
        <zip>SS16 5NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Davies, MRCP PhD</last_name>
      <phone>01268 524900</phone>
      <email>john.davies32@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Sarosh Khan, MRCP</last_name>
      <phone>01268 524900</phone>
      <phone_ext>4211</phone_ext>
      <email>sarosh.khan2@nhs.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter O'Kane, MRCP MD</last_name>
      <email>peter.o'kane@uhd.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angina</keyword>
  <keyword>Chronic total occlusion</keyword>
  <keyword>Angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

